Midwest Biomedical Accelerator Consortium: MBArC

中西部生物医学加速器联盟:MBArC

基本信息

  • 批准号:
    10240635
  • 负责人:
  • 金额:
    $ 98.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-23 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract The ultimate goal of biomedical research is to create new devices, drugs, and technologies that prevent, diagnose, and treat human diseases. Like scientific discovery, biomedical technology commercialization is complex and requires mentorship, resources, collaboration, and risk. However, several hurdles limit commercialization of promising laboratory discoveries, including 1) lack of awareness by academicians that commercialization is an option, 2) concerns that commercialization efforts delay academic advancement, and 3) failure to connect investigators with the collaborators and experts necessary to complete the commercialization process. The objective of this Research Evaluation and Commercialization Hub (REACH) proposal is to establish a partnership between the University of Missouri-Columbia (MU) and the University of Kansas Medical Center (KUMC) that will promote academic entrepreneurship and commercialization. To this collaboration MU brings its outstanding biomedical and bioengineering research programs and its vibrant track record of participation in the Coulter Translational Research Partnership Award program. KUMC provides its exceptional biomedical research programs and Frontiers, its NIH Clinical and Translational Science Award (CTSA). In addition, each institution has existing partnerships that strengthen and extend the alliance - i.e. 1) MU with University of Missouri state system universities in Kansas City, St. Louis, and Rolla; and 2) KUMC with the Kansas Idea Network of Biomedical Research Excellence (K-INBRE) and the Sustainable Heartland Accelerator Regional Partnership Hub (SHARPhub). The leadership team of this network, entitled the Midwest Biomedical Accelerator Consortium (MBArC), will employ the following strategies to increase biomedical research commercialization: 1) leverage MBArC’s geographic and institutional scope to develop strategic partnerships that invite scientists to engage in technology transfer and commercialization, 2) give academicians the training and resources needed to validate the clinical and commercial feasibility of their innovations, 3) provide researchers with funding and mentorship to complete product definition studies and attract follow- on funding, and 4) offer experiential learning opportunities in biomedical innovation and entrepreneurship. This initiative will build on existing programs in outstanding institutions to increase health-related business development, including small businesses, in Missouri, Kansas, and adjoining states. The MBArC REACH Hub will promote commercialization of novel scientific discoveries and establish a sustainable infrastructure to translate scientific discoveries into commercial products that prevent and treat high-burden diseases afflicting the US population.
项目总结/摘要 生物医学研究的最终目标是创造新的设备,药物和技术, 预防、诊断和治疗人类疾病。比如科学发现,生物医学技术 商业化是复杂的,需要指导、资源、协作和风险。 然而,一些障碍限制了有前途的实验室发现的商业化,包括 1)学术界缺乏对商业化是一种选择的认识,2)担心 商业化努力延迟学术进步,3)未能连接研究人员 与合作者和专家一起完成商业化过程。的 该研究评估和商业化中心(REACH)提案的目标是 建立密苏里-哥伦比亚大学(MU)和密苏里大学之间的伙伴关系, 堪萨斯医疗中心(KUMC)将促进学术创业, 商业化在这次合作中,MU带来了其杰出的生物医学和生物工程 研究计划及其参与库尔特翻译的充满活力的记录 研究合作伙伴奖计划。KUMC提供其卓越的生物医学研究 项目和前沿,其NIH临床和转化科学奖(CTSA)。此外,本发明还提供了一种方法, 每个机构都有现有的伙伴关系,加强和扩大联盟-即1)MU与 密苏里州州立系统大学,位于堪萨斯城、圣路易斯和罗拉; 2)KUMC 与堪萨斯生物医学研究卓越理念网络(K-INBRE)和可持续发展 Heartland Accelerator Regional Partnership Hub(SHARPhub)该组织的领导团队 一个名为中西部生物医学加速器联盟(MBArC)的网络将采用 以下战略,以提高生物医学研究的商业化:1)利用MBArC的 发展战略伙伴关系,邀请科学家 从事技术转让和商业化,2)培养院士, 验证其创新的临床和商业可行性所需的资源,3)提供 研究人员与资金和指导,以完成产品定义研究,并吸引以下- 4)提供生物医学创新方面的体验式学习机会, 创业这项倡议将建立在优秀机构的现有方案的基础上, 在密苏里州、堪萨斯 和相邻的国家。MBArC REACH Hub将促进新科学技术的商业化 建立可持续的基础设施,将科学发现转化为 预防和治疗困扰美国人口的高负担疾病的商业产品。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William P Fay其他文献

William P Fay的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William P Fay', 18)}}的其他基金

Role of Plasminogen Activator Inhibitor-1 in Vascular Smooth Muscle Cell Stiffening and Senescence
纤溶酶原激活剂抑制剂 1 在血管平滑肌细胞硬化和衰老中的作用
  • 批准号:
    10512042
  • 财政年份:
    2021
  • 资助金额:
    $ 98.1万
  • 项目类别:
Role of Plasminogen Activator Inhibitor-1 in Vascular Smooth Muscle Cell Stiffening and Senescence
纤溶酶原激活剂抑制剂 1 在血管平滑肌细胞硬化和衰老中的作用
  • 批准号:
    10259921
  • 财政年份:
    2021
  • 资助金额:
    $ 98.1万
  • 项目类别:
Midwest Biomedical Accelerator Consortium: MBArC
中西部生物医学加速器联盟:MBArC
  • 批准号:
    10312631
  • 财政年份:
    2020
  • 资助金额:
    $ 98.1万
  • 项目类别:
Midwest Biomedical Accelerator Consortium: MBArC
中西部生物医学加速器联盟:MBArC
  • 批准号:
    10230468
  • 财政年份:
    2020
  • 资助金额:
    $ 98.1万
  • 项目类别:
Midwest Biomedical Accelerator Consortium: MBArC
中西部生物医学加速器联盟:MBArC
  • 批准号:
    10475264
  • 财政年份:
    2019
  • 资助金额:
    $ 98.1万
  • 项目类别:
Midwest Biomedical Accelerator Consortium: MBArC
中西部生物医学加速器联盟:MBArC
  • 批准号:
    10730211
  • 财政年份:
    2019
  • 资助金额:
    $ 98.1万
  • 项目类别:
Midwest Biomedical Accelerator Consortium: MBArC
中西部生物医学加速器联盟:MBArC
  • 批准号:
    10022343
  • 财政年份:
    2019
  • 资助金额:
    $ 98.1万
  • 项目类别:
Midwest Biomedical Accelerator Consortium: MBArC
中西部生物医学加速器联盟:MBArC
  • 批准号:
    9897387
  • 财政年份:
    2019
  • 资助金额:
    $ 98.1万
  • 项目类别:
Role of Plasminogen Activator Inhibitor-1 in Adipose Tissue Dysfunction and Atherosclerosis in Metabolic Syndrome
纤溶酶原激活剂抑制剂 1 在代谢综合征脂肪组织功能障碍和动脉粥样硬化中的作用
  • 批准号:
    9913573
  • 财政年份:
    2018
  • 资助金额:
    $ 98.1万
  • 项目类别:
Role of Plasminogen Activator Inhibitor-1 in Adipose Tissue Dysfunction and Atherosclerosis in Metabolic Syndrome
纤溶酶原激活剂抑制剂 1 在代谢综合征脂肪组织功能障碍和动脉粥样硬化中的作用
  • 批准号:
    10155514
  • 财政年份:
    2018
  • 资助金额:
    $ 98.1万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 98.1万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 98.1万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 98.1万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 98.1万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 98.1万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 98.1万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 98.1万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 98.1万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 98.1万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 98.1万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了